<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543932</url>
  </required_header>
  <id_info>
    <org_study_id>TRIPLETE RESET</org_study_id>
    <nct_id>NCT01543932</nct_id>
  </id_info>
  <brief_title>High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients</brief_title>
  <acronym>TRIPLETE RESET</acronym>
  <official_title>Comparison of Therapy With TICAGRELOR, Prasugrel and High Clopidogrel Dose in PCI Patients With High on Treatment Platelet Reactivity and Genotype Variation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual antiplatelet therapy with Aspirin and Clopidogrel for at least one year is essential in&#xD;
      patients following an acute coronary syndrome (ACS) or percutaneous coronary intervention&#xD;
      (PCI) with drug eluting stent(s) implantation. Interindividual variability in platelet&#xD;
      response to Clopidogrel has been reported, with several mechanisms (intrinsic high platelet&#xD;
      reactivity [PR], variability of the drug metabolism, and various drug interactions) being&#xD;
      implicated for high post-Clopidogrel treatment PR. The investigators aim to perform a&#xD;
      prospective, single-center, investigator-initiated, randomized, study to compare platelet&#xD;
      inhibition by Prasugrel 10 mg/day, Ticagrelor (90 mg twice daily) and high-dose 150 mg/day&#xD;
      Clopidogrel in patients with High on-treatment platelet reactivity (HTPR) with standard dose&#xD;
      of Clopidogrel. Patients with HTPR (defined as area under curve-AUC ≥ 450 or &gt; 45 Unit) and&#xD;
      with loss-of-function allele CYP2C19*2 will be enrolled in the study and will be randomized&#xD;
      (Day 0) in a 1:1:1 ratio, to either Clopidogrel 150 mg a day or Prasugrel 10 mg a day or&#xD;
      Ticagrelor (90 mg twice daily) until Day-15 and-30 post randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>antiplatelet effect of standard dose of prasugrel or ticagrelor versus high dose clopidogrel in stable patients with high reactivity</measure>
    <time_frame>30 days</time_frame>
    <description>the antiplatelet effect in terms of level platelet reactivity (&lt; 450 Area under the curve (AU*min)) of standard dose of Prasugrel (10 mg/day) either Ticagrelor (90 mg twice daily) versus high dose Clopidogrel (150 mg/day) in patients undergoing PCI with high reactivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding (major, minor, or minimal)</measure>
    <time_frame>45 days</time_frame>
    <description>Bleeding (major, minor, or minimal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Cerebrovascular Events</measure>
    <time_frame>45 days</time_frame>
    <description>cardiovascular death, myocardial infarction, and stroke</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Prasugrel standard dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high clopidogrel dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 15 days and 30 days we will control the responsivness of the study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor standard dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be randomized to this intervention will receive in the first time ticagrelor and after 15 days and 30 days we will control the responsivness of the study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.</description>
    <arm_group_label>high clopidogrel dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.</description>
    <arm_group_label>Prasugrel standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).</description>
    <arm_group_label>Ticagrelor standard dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients underwent to percutaneous coronary intervention (PCI)&#xD;
&#xD;
          -  clopidogrel resistance after Platelet reactivity blood test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of bleeding diathesis&#xD;
&#xD;
          -  chronic oral anticoagulation treatment&#xD;
&#xD;
          -  contraindications to antiplatelet therapy&#xD;
&#xD;
          -  PCI or coronary artery bypass grafting (CABG) &lt; 3 months&#xD;
&#xD;
          -  hemodynamic instability&#xD;
&#xD;
          -  platelet count &lt; 100,000/μl&#xD;
&#xD;
          -  hematocrit &lt; 30%&#xD;
&#xD;
          -  creatinine clearance &lt; 25 ml/min&#xD;
&#xD;
          -  Patients with a history of stroke&#xD;
&#xD;
          -  contraindication for prasugrel administration&#xD;
&#xD;
          -  patients weighing &lt; 60 kg&#xD;
&#xD;
          -  &gt; 75 years of age.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept.of Cardiovascular Sciences,Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>000161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Gennaro Sardella</investigator_full_name>
    <investigator_title>Associate Professor in Cardiology</investigator_title>
  </responsible_party>
  <keyword>antiplatelet effect</keyword>
  <keyword>prasugrel</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>stable angina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

